RecruitingPhase 1NCT06544720

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas

Sponsor

The Affiliated Hospital of Qingdao University

Enrollment

18 participants

Start Date

Aug 2, 2023

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer Anal Cancer Penile Cancer Vaginal Cancer Head and Neck Cancers Vulva Cancer Human Papillomavirus Associated Carcinomas HPV-Related Malignancy

Summary

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of immune cell therapy called SCG142 — a T-cell treatment engineered to recognize HPV proteins — in people with cancers caused by the human papillomavirus (HPV), such as cervical, head and neck, or anal cancer. **You may be eligible if...** - You are 18 or older with an HPV-associated cancer - You have at least one measurable tumor on imaging - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - You have uncontrolled infections or serious heart or lung conditions - You have an active autoimmune disease - You have active hepatitis B or hepatitis C - You have other severe medical conditions that limit participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.